Stellenwert klinischer, funktioneller und bildgebender Diagnostik zur Früherkennung, Differenzialdiagnose und Verlaufskontrolle diabetischer Neuropathien

Maike F. Dohrn; Natalie Winter; Christina Dumke; Friederike Bähr; Annabelle Ouwenbroek; Barbara Hoppe; Karlheinz Reiners; Manuel Dafotakis

doi:10.1055/a-1335-1086

Klinische Neurophysiologie, Table of Contents

Klinische Neurophysiologie 2021; 52(02): 92-104
DOI: 10.1055/a-1335-1086

Originalia

Stellenwert klinischer, funktioneller und bildgebender Diagnostik zur Früherkennung, Differenzialdiagnose und Verlaufskontrolle diabetischer Neuropathien

The Role of Clinical, Functional, and Imaging Diagnostics for Early Detection, Differential Diagnosis, and Monitoring of Diabetic Neuropathies

Maike F. Dohrn

¹Neurologie, Uniklinik der RWTH Aachen, Aachen, Deutschland

,

Natalie Winter

²Neurologie, Universitätsklinikum Tübingen, Tübingen, Deutschland

,

Christina Dumke

¹Neurologie, Uniklinik der RWTH Aachen, Aachen, Deutschland

,

Friederike Bähr

¹Neurologie, Uniklinik der RWTH Aachen, Aachen, Deutschland

,

Annabelle Ouwenbroek

¹Neurologie, Uniklinik der RWTH Aachen, Aachen, Deutschland

,

Barbara Hoppe

³Neurologie, Klinikum Köln-Merheim, Köln, Deutschland

,

Karlheinz Reiners

⁴Neurologie, Hermann-Josef-Krankenhaus Erkelenz, Erkelenz, Deutschland

,

Manuel Dafotakis

¹Neurologie, Uniklinik der RWTH Aachen, Aachen, Deutschland

› Author Affiliations

Abstract

Zusammenfassung

Von weltweit mehr als 400 Mio. Menschen mit Diabetes mellitus entwickeln bis zu 50% im Laufe ihrer Erkrankung eine Neuropathie. Trotz oder gerade wegen dieser Häufigkeit darf jedoch nicht jede Neuropathie, die in Koinzidenz mit einem Diabetes mellitus auftritt, unkritisch als diabetische Neuropathie diagnostiziert werden. Eine präzise Ausschluss- und Ausmaßdiagnostik ist entscheidend, um andere behandelbare Erkrankungen wie z. B. die Chronisch Inflammatorische Demyelinisierende Polyradikuloneuropathie oder die hereditäre Transthyretin-Amyloidose nicht zu übersehen. Einfache, nicht-invasive, preiswerte und allzeit verfügbare Screeningmethoden stellen Anamnese und klinische Untersuchung dar. Ergänzend ist in frühen Erkrankungsstadien die Quantitativ Sensorische Testung hilfreich zur Eingrenzung einer Small Fiber-Dysfunktion. Sind, typischerweise im Verlauf, große Nervenfasern geschädigt, so ist das charakteristische elektrophysiologische Bild das einer längenabhängigen, axonalen, sensibel betonten oder sensomotorischen Neuropathie. Die Nervensonografie kann zur Unterscheidung von autoimmun-demyelinisierenden Neuropathien hilfreich sein. Moderne Untersuchungsverfahren wie die MR-Neurografie können auch proximale Nervenabschnitte bis auf Faszikelebene darstellen, sind allerdings nur an wenigen Zentren verfügbar. Haut- und Nervenbiopsien sind v. a. bei untypischen Verläufen zur Abgrenzung von Differenzialdiagnosen hilfreich. Diabetische Neuropathien können zu einer erheblichen Reduktion von Lebensqualität und Lebensdauer führen. Zur frühest- und bestmöglichen ursächlichen und symptomatischen Therapieeinleitung ist eine präzise Diagnostik essentiell.

Abstract

Out of 400 million individuals with diabetes mellitus worldwide, up to 50% will develop some form of neuropathy during the course of the disease. However, not every neuropathy occurring along with diabetes mellitus can be considered as diabetic neuropathy. Precise diagnostic methods are required not to miss other treatable diseases, e. g., chronic inflammatory demyelinating polyradiculoneuropathy or hereditary transthyretin-related amyloidosis. Patient history and neurological examinations constitute easy, non-invasive, cost-efficient, and readily available screening tools. In early stages, quantitative sensory testing is helpful in evaluating small fiber dysfunction. When large fibers are damaged, nerve conduction studies show a length-dependent, axonal, sensory or sensorimotor neuropathy. The nerve ultrasound can be helpful to distinguish diabetic from autoimmune neuropathy. MRI neurography has the potential to depict even proximal nerve sections up to fascicle levels, but is available at highly specialized centers only. Skin and nerve biopsies are still of use to identify competing causes in atypical cases. Diabetic neuropathies can drastically reduce the span and quality of life. Precise diagnostic procedures are essential for identifying the best and earliest causative and symptomatic treatment.

Schlüsselwörter

Diabetische Neuropathie - Neurologische Differenzialdiagnostik - Elektroneurographie - Quantitativ Sensorische Testung - Autonome Funktionsdiagnostik

Key words

Diabetic neuropathy - neurological differential diagnostic - nerve conduction studies - quantitative sensory testing - autonomic diagnostic

Full Text

References

Literatur
1 Harris M, Eastman R, Cowie C. Symptoms of sensory neuropathy in adults with NIDDM in the US population. Diabetes Care 1993; 16: 1446
2 Obrosova I. Update on the pathogenesis of diabetic neuropathy. Curr Diab Rep 2003; 3: 439
3 Pasnoor M, Dimachkie M, Kluding P. et al. Diabetic neuropathy part 1: overview and symmetric phenotypes. Neurol Clin 2013; 31: 425
4 Dyck P. nerve: Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988; 11: 21
5 Dohrn M, Othman A, Hirshman S. et al Elevation of plasma 1-deoxy-sphingolipids in type 2 diabetes mellitus: a susceptibility to neuropathy?. Eur J Neurol 2015; 22: 806
6 Singleton J, Smith A, Bromberg M. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 2001; 24: 1225
7 Ziegler D, Landgraf R, Lobmann R. et al. Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (PROTECT study). Diabetes Res Clin Pract 2018; 139: 147-154
8 Ziegler D, Landgraf R, Lobmann R. et al. Polyneuropathy is inadequately treated despite increasing symptom intensity in individuals with and without diabetes (PROTECT follow-up study). J Diabetes Investig. 2020
9 Sämann A, Tajiyeva O, Müller N. et al. Prevalence of the diabetic foot syndrome at the primary care level in Germany: a cross-sectional study. Diabet Med 2008; 25: 557
10 AWMF: Neuropathie bei Diabetes im Erwachsenenalter Diabetologie. 2012
11 Ziegler D, Keller J, Maier C. et al. Diabetic neuropathy. Exp Clin Endocrinol Diabetes 2014; 122: 406
12 Pop-Busui R, Boulton AJ, Feldman EL. et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017; 40: 136
13 Laughlin RS, Dyck PJ, Melton LJ. et al. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009; 73: 39
14 Dohrn M, Röcken C, De Bleecker J. et al. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol 2013; 260: 3093
15 Dyck P, Albers J, Andersen H. et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev 2011; 27: 620
16 Albers JW, Pop-Busui R. Diabetic Neuropathy: Mechanisms, Emerging Treatments, and Subtypes. Curr Neurol Neurosci Rep 2014; 14: 473
17 Dyck PJ, Kratz K, Karnes J. et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817-817
18 O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009; 122: 22-32
19 Sommer C, Geber C, Young P. et al. Polyneuropathies. Dtsch Arztebl Int 2018; 115: 83
20 Albers JW, Jacobson RD, Smyth DL. Diabetic Amyotrophy: From the Basics to the Bedside. EMJ 2020; 5: 94-103
21 Tesfaye S, Chaturvedi N, Eaton S. et al. Group EPCS Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341
22 Sandireddy R, Yerra VG, Areti A. et al. Neuroinflammation and Oxidative Stress in Diabetic Neuropathy: Futuristic Strategies Based on These Targets. Int J Endocrinol. 2014
23 Callaghan BC, Cheng H, Stables CL. et al. Diabetic neuropathy: Clinical manifestations and current treatments. Lancet Neurol 2012; 11: 521
24 Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain 2015; 138: 43
25 Dohrn MF, Kessler S, Dafotakis M. Die Rolle der diabetischen Neuropathie bei der Genese des Charcot-Fußes. Klin Neurophysiol 2020; 51: 67-72
26 Burke D, Skuse NF, Lethlean AK. Sensory conduction of the sural nerve in polyneuropathy. J Neurol Neurosurg Psychiatry 1974; 37: 647
27 Sima AA, Kamiya H. Diabetic neuropathy differs in type 1 and type 2 diabetes. Ann N Y Acad Sci 2006; 1084: 235-249
28 Krishnan A, Kiernan M. Altered nerve excitability properties in established diabetic neuropathy. Brain 2005; 128: 1178
29 Wilson J, Stittsworth J, Kadir A. et al. Conduction velocity vs. amplitude analysis: evidence for demyelination in diabetic neuropathy. Muscle Nerve 1998; 21: 1228
30 Gorson K, Ropper A, Adelman L. et al. Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2000; 23: 37
31 Bril V, Blanchette CM, Noone JM. et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complications 2016; 30: 1401
32 Ziegler D, Mühlen H, Gries F. Neurophysiological tests in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients with subclinical and symptomatic neuropathy. Diabetologia 1992; 35: 1099
33 Løseth S, Mellgren S, Jorde R. et al. Polyneuropathy in type 1 and type 2 diabetes: comparison of nerve conduction studies, thermal perception thresholds and intraepidermal nerve fibre densities. Diabetes Metab Res Rev 2010; 26: 100
34 Baum P, Hermann W, Verlohren H. et al. Diabetic neuropathy in patients with “latent autoimmune diabetes of the adults” (LADA) compared with patients with type 1 and type 2 diabetes. J Neurol 2003; 250: 682
35 Mücke M, Cuhls H, Radbruch L. et al. Quantitative sensory testing (QST). English version. Schmerz. 2016
36 Rolke R, Magerl W, Campbell KA. et al. Quantitative sensory testing: a comprehensive protocol for clinical trials. Pain 2006; 10: 77-88
37 Ewing D, Boland O, Neilson J. et al. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia 1991; 34: 182
38 Ziegler D, Zentai C, Perz S. et al. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care 2008; 31: 556
39 Sletten DM, Weigand SD, Low PA. Relationship of Q-Sweat to Quantitative Sudomotor Axon Reflex Test (QSART) Volumes. Muscle Nerve 2010; 41: 240
40 Pitarokoili K, Kerasnoudis A, Behrendt V. et al. Facing the diagnostic challenge: Nerve ultrasound in diabetic patients with neuropathic symptoms. Muscle Nerve 2016; 54: 18-24
41 Watanabe T, Ito H, Sekine A. et al. Sonographic evaluation of the peripheral nerve in diabetic patients: the relationship between nerve conduction studies, echo intensity, and cross-sectional area. J Ultrasound Med 2010; 29: 697
42 Hobson-Webb L, Massey J, Juel V. Nerve ultrasound in diabetic polyneuropathy: correlation with clinical characteristics and electrodiagnostic testing. Muscle Nerve 2013; 47: 379
43 Lee D, Dauphinée D. Morphological and functional changes in the diabetic peripheral nerve: using diagnostic ultrasound and neurosensory testing to select candidates for nerve decompression. J Am Podiatr Med Assoc 2005; 95: 433
44 Tan C, Arumugam T, Razali S. et al. Nerve ultrasound can distinguish chronic inflammatory demyelinating polyneuropathy from demyelinating diabetic sensorimotor polyneuropathy. J Clin Neurosci 2018; 57: 198
45 Vaeggemose M, Haakma W, Pham M. et al. Diffusion tensor imaging MR Neurography detects polyneuropathy in type 2 diabetes. J Diabetes Complications 2020; 34: 107439
46 Vaeggemose M, Pham M, Ringgaard S. et al. Diffusion tensor imaging MR neurography for the detection of polyneuropathy in type 1 diabetes. J Magn Reson Imaging 2017; 45: 1125
47 Pham M, Oikonomou D, Bäumer P. et al. Proximal Neuropathic Lesions in Distal Symmetric Diabetic Polyneuropathy: Findings of high-resolution magnetic resonance neurography. Diabetes Care 2011; 34: 721
48 Thakkar R, Del Grande F, Thawait G. et al. Spectrum of high-resolution MRI findings in diabetic neuropathy. AJR Am J Roentgenol 2012; 199: 407
49 Sima A. Zhang WJHocn: Mechanisms of diabetic neuropathy: axon dysfunction. Handb Clin Neurol 2014; 126: 429
50 Malik R, Tesfaye S, Newrick P. et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia 2005; 48: 578
51 Weis J, Schröder JM, Dimpfel W. Nerve conduction changes and fine structural alterations of extra-and intrafusal muscle and nerve fibers in streptozotocin diabetic rats. Muscle Nerve 1995; 18: 175-184
52 Flachenecker P, Janka M, Goldbrunner R. et al. Clinical outcome of sural nerve biopsy: a retrospective study. J Neurol 1999; 246: 93
53 Sommer C. Nerve and skin biopsy in neuropathies. Curr Opin Neurol 2018; 31: 534
54 Pasnoor M, Dimachkie M, Barohn R. Diabetic neuropathy part 2: proximal and asymmetric phenotypes. Neurol Clin 2013; 31: 447
55 Jiang M-S, Yuan Y, Gu Z-X. et al. Corneal confocal microscopy for assessment of diabetic peripheral neuropathy: a meta-analysis. Br J Ophthalmol 2016; 100: 9-14
56 Perkins BA, Lovblom LE, Bril V. et al. Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. Diabetologia 2018; 61: 1856-1861
57 Tavakoli M, Quattrini C, Abbott C. et al. Corneal Confocal Microscopy: A novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care 2010; 33: 1792
58 Penno A, Reilly MM, Houlden H. et al. Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J Biol Chem 2010; 285: 11178-11187
59 Wile DJ, Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care 2010; 33: 156-161
60 Haq RU, Pendlebury WW, Fries TJ. et al. Chronic inflammatory demyelinating polyradiculoneuropathy in diabetic patients. Muscle Nerve 2003; 27: 465-470
61 Lozeron P, Nahum L, Lacroix C. et al. Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients. J Neurol 2002; 249: 569
62 Isose S, Kuwabara S, Kokubun N. et al. Utility of the distal compound muscle action potential duration for diagnosis of demyelinating neuropathies. J Peripher Nerv Syst 2009; 14: 151
63 Cleland J, Malik K, Thaisetthawatkul P. et al. Acute inflammatory demyelinating polyneuropathy: contribution of a dispersed distal compound muscle action potential to electrodiagnosis. Muscle Nerve 2006; 33: 771
64 Perkins BA, Olaleye D, Bril V. Carpal tunnel syndrome in patients with diabetic polyneuropathy. Diabetes Care 2002; 25: 565-569
65 Dellon A. Treatment of symptoms of diabetic neuropathy by peripheral nerve decompression. Plast Reconstr Surg 1992; 89: 689-697
66 Chaudhry V, Russell J, Belzberg A. Decompressive surgery of lower limbs for symmetrical diabetic peripheral neuropathy. Cochrane Database Syst Rev. 2008